International Circulation:  Finally， what is the present situation regarding clinical application of aliskiren in Europe?

国际循环: 最后一个问题，阿利吉仑目前在欧洲的临床应用情况如何？

Gonzalez Juanatey教授: 在欧洲，明确的适应证是高血压。目前唯一获得批准的适应证就是治疗高血压患者。正如我之前所提到的，阿利吉仑具有治疗全部疾病谱、各种类型高血压的很好记录。最重要的是，阿利吉仑联合利尿剂、钙通道拮抗剂、甚至ACEI或者ARB治疗高血压的记录情况目前很有希望。在欧洲，我们有确定的联合一种利尿剂氢氯噻嗪的用药方案，而其降压效果很重要。 我相信，在不久的将来，将可以应用其它联合ARB或者钙通道阻断剂的用药方案。前景确实非常令人激动，因为我们正在观察在高危患者、糖尿病患者、充血性心力衰竭患者以及心梗后患者中进行的生存和预后研究。我认为，这是药物预防与高血压有关的血管和肾脏功能不全的新纪元。

Gonzalez Juanatey:  In Europe， the clear indication is hypertension.  At present， the unique approved indication is treating hypertensive patients.  As I mentioned before， aliskiren has a very good profile for treating all types of hypertension throughout the entire spectrum.  Most importantly， the combined profile of hypertension treatment with aliskiren combined with diuretics， with calcium antagonists， even ACE or ARBs is promising at present.  In Europe we have a fixed combination with chlorothiozides with a diuretic and the anti-hypertensive effect is important.  I believe other combinations will be available in the near future with ARB or with calcium channel blockers.  The future is really exciting because we are looking survival and prognostic studies in high-risk patients as well as in diabetic patients， congestive heart failure patients， and post-MI patients.  I think it is a new era in pharmacologic